0000950170-24-085347.txt : 20240722 0000950170-24-085347.hdr.sgml : 20240722 20240722172509 ACCESSION NUMBER: 0000950170-24-085347 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240721 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240722 DATE AS OF CHANGE: 20240722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEI Pharma, Inc. CENTRAL INDEX KEY: 0001262104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 510407811 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41827 FILM NUMBER: 241132353 BUSINESS ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-369-7100 MAIL ADDRESS: STREET 1: 11455 EL CAMINO REAL STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: MARSHALL EDWARDS INC DATE OF NAME CHANGE: 20030902 8-K 1 meip-20240722.htm 8-K 8-K
0001262104false00012621042024-07-222024-07-22

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 21, 2024

 

 

MEI Pharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41827

51-0407811

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

11455 El Camino Real, Suite 250

 

San Diego, California

 

92130

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 369-7100

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.00000002 par value

 

MEIP

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.05 Costs Associated with Exit or Disposal Activities.

On July 22, 2024, MEI Pharma, Inc. (the “Company”) announced that its Board of Directors (the “Board”) has determined unanimously to begin an evaluation of the Company’s strategic alternatives, including potential transactions as well as an orderly wind-down of the Company, if necessary, in order to maximize the value of its assets. In connection with these activities, and in order to best preserve the Company’s existing cash, the Company will commence a reduction-in-force beginning as soon as practicable and continuing in stages as the Company’s operational and strategic direction evolves. The Company also intends to promptly discontinue the clinical development of voruciclib, while continuing to conduct certain non-clinical activities related to the Company’s drug candidate assets.

This workforce reduction will commence during the first quarter of the Company’s fiscal year ending June 30, 2025 (“fiscal 2025”) and continue through the year as appropriate in light of the evaluation of strategic alternatives. As a result of these actions, the Company expects to incur personnel-related restructuring charges of approximately $5.8 million in connection with one-time employee termination costs, including severance and other benefits, which are expected to be recognized in the first quarter of fiscal 2025. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction or retention efforts. These estimates of the costs that the Company expects to incur, and the timing thereof, are subject to a number of assumptions and actual results may differ.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the approval of the review of strategic alternatives and the planned reduction-in-force, as discussed in Item 2.05 above, David M. Urso, our President and Chief Executive Officer, and Richard G. Ghalie, M.D., our Chief Medical Officer, will be leaving the Company effective August 1, 2024. Mr. Urso will also leave the Board at that time. In the case of each of these departures, the Board has determined that Mr. Urso and Dr. Ghalie will be eligible to receive severance benefits commensurate with a termination without “Cause” or a termination for “Good Reason” under their respective employment agreements with the Company, as previously filed with the Securities and Exchange Commission (the “SEC”) and incorporated herein by reference to Exhibit 10.15 of the Company’s Annual Report on Form 10-K, filed with the SEC on June 29, 2023 and Exhibit 10.4 of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on February 13, 2024.

The Company expects to enter into a separation agreement with each of Mr. Urso and Dr. Ghalie, and also to enter into consulting agreements with each of them in order to engage their services as consultants to assist in the matters discussed in Item 2.05 above. The terms of such agreements will be disclosed by the Company when the agreements are entered into.

Appointment of Justin J. File as Acting Chief Executive Officer

The Board has appointed Justin J. File, age 53, currently the Company’s Chief Financial Officer and Secretary, to serve in the additional capacity of Acting Chief Executive Officer (“Acting CEO”), effective as of August 1, 2024. There are no arrangements or understandings between Mr. File and any other person pursuant to which he was selected as Acting CEO, and there are no family relationships between Mr. File and any of the Company’s directors or executive officers. Mr. File has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under item 404(a) of Regulation S-K.

In connection with his appointment as Acting CEO, the Board expects to enter into an amendment to Mr. File’s employment agreement, as previously filed with the SEC and incorporated herein by reference to Exhibit 10.17 of the Company’s Annual Report on Form 10-K, filed with the SEC on June 29, 2023, to increase his base salary to $550,000 and to increase his bonus opportunity, as a percentage of his base salary, from 40% to 50%.

The Company expects to enter into an addendum to Mr. File’s employment agreement to memorialize these and any other changes to which Mr. File and the Company may agree. The terms of this addendum will be disclosed by the Company when it is entered into.

In connection with these matters, Charles V. Baltic III, the current Chairperson of the Board, will also step down from the Board effective immediately. The Board has appointed Frederick W. Driscoll as Chairperson of the Company.

Item 7.01 Regulation FD Disclosure.

On July 22, 2024, the Company issued a press release announcing the matters discussed in Item 2.05 above. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.6 and is incorporated herein by reference.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press Release issued by MEI Pharma, Inc., dated July 22, 2024.

104

Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MEI Pharma, Inc.

 

 

 

 

Date:

July 22, 2024

By:

/s/ Justin J. File

 

 

 

Justin J. FIle
Chief Financial Officer and Secretary

 

 EX-99.1 2 meip-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

 

MEI Pharma to Consider Strategic Alternatives

 

Company Commences a Cash Preservation Plan Including a Reduction in Force

 

SAN DIEGO--(BUSINESS WIRE)—July 22, 2024 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process.

 

In order to best preserve the Company’s existing cash, the Company will commence a reduction-in-force beginning as soon as practicable and continuing in stages as the Company’s operational and strategic direction evolves. The Company intends to promptly discontinue the clinical development of voruciclib, while certain non-clinical activities related to MEI’s drug candidate assets will continue to be conducted by the Company.

 

Consistent with the Company’s intention to preserve the cash, David M. Urso, the Company’s President and Chief Executive Officer, and Richard Ghalie, MD, the Company’s Chief Medical Officer, have agreed in principle with the Company to step down, effective as of August 1, 2024. Mr. Urso will also leave the Company’s Board of Directors at that time. The Company expects to enter into consulting agreements with both Mr. Urso and Dr. Ghalie under which they will remain available to assist the Company in its strategic efforts. Charles V. Baltic III, the current Chairperson of the Company’s Board of Directors, will also step down from the Board contemporaneous with this announcement.

 

As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.

 

The Company’s Board of Directors has appointed Justin “Jay” File, currently the Company’s Chief Financial Officer, to assume the position of Acting Chief Executive Officer upon Mr. Urso’s departure to lead the Company through this period of transition. The Board of Directors has also appointed Frederick W. Driscoll Chairperson of the Company to lead the Board during this period.

 

“The Company has reached an important transition point that will focus on the evaluation of alternate strategic pathways in the interests of all MEI stockholders. While MEI has decided to cease clinical development activities of its drug candidate portfolio, these activities have contributed meaningfully to scientific understanding and clinical experience in kinase inhibition and metabolic pathways relevant to hematologic and solid cancers. It has been a privilege to serve the Company and its stockholders as Chairperson through its recent evolution. I thank David Urso for his leadership and all MEI employees for their dedication and professionalism” stated Mr. Baltic.

 

Mr. Urso stated “I thank the Board for their support of me and of the dedicated MEI staff in their intrepid efforts. I would also like to thank MEI’s employees for their incredible professionalism and commitment to oncology drug development. I finally want to thank the many cancer patients and clinicians who have participated in MEI sponsored clinical trials in support of evaluating potential new cancer therapies. I believe that MEI, its employees and these patients and clinicians have significantly helped to advance understanding of experimental cancer therapies.”

 

“The Company’s Board and management team believe that it is prudent to focus the Company’s resources and efforts on the exploration of potential strategic alternatives, and during that process to practice prudent cash management,” said Mr. File. “Should advantageous strategic alternatives not be presented, the Company would consider an orderly wind down of its operations.”

 

About MEI Pharma

 

MEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company committed to developing novel and differentiated cancer therapies. We build our pipeline by acquiring promising cancer agents and creating value in

programs through development, strategic partnerships, out-licensing and commercialization, as appropriate. Our approach to oncology drug development is to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.

 

Forward-Looking Statements

 

Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation and the increase in interest rates as a result; potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

 

Contacts

 

David A. Walsey

858-369-7104

investor@meipharma.com

 

 

 

 EX-101.SCH 3 meip-20240722.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Document And Entity Information
Jul. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 21, 2024
Entity Registrant Name MEI Pharma, Inc.
Entity Central Index Key 0001262104
Entity Emerging Growth Company false
Entity File Number 001-41827
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 51-0407811
Entity Address, Address Line One 11455 El Camino Real, Suite 250
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 369-7100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.00000002 par value
Trading Symbol MEIP
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports meip-20240722.htm meip-20240722.xsd http://xbrl.sec.gov/dei/2024 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "meip-20240722.htm": { "nsprefix": "meip", "nsuri": "http://www.meipharma.com/20240722", "dts": { "inline": { "local": [ "meip-20240722.htm" ] }, "schema": { "local": [ "meip-20240722.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_cbffebeb-509f-459e-94ca-254e8a217aa2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "meip-20240722.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cbffebeb-509f-459e-94ca-254e8a217aa2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "meip-20240722.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.meipharma.com/20240722/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-085347-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-085347-xbrl.zip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meip-20240722_htm.xml IDEA: XBRL DOCUMENT 0001262104 2024-07-22 2024-07-22 0001262104 false 8-K 2024-07-21 MEI Pharma, Inc. DE 001-41827 51-0407811 11455 El Camino Real, Suite 250 San Diego CA 92130 858 369-7100 false false false false Common Stock, $0.00000002 par value MEIP NASDAQ false